Back to top
more

Amphastar Pharmaceuticals (AMPH)

(Delayed Data from NSDQ)

$21.21 USD

21.21
440,154

+0.26 (1.24%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $21.21 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Amphastar (AMPH) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Amphastar (AMPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Amphastar (AMPH) delivered earnings and revenue surprises of 37.78% and 7.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bausch Health (BHC) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Bausch (BHC) delivered earnings and revenue surprises of -30.67% and 0.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

Zacks Equity Research

Zacks.com featured highlights Amphastar, Alpha Metallurgical and Riley Exploration

by Zacks Equity Research

Amphastar, Alpha Metallurgical and Riley Exploration have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Profitable Stocks Worth a Buy Using Net Income Ratio

by Tirthankar Chakraborty

Amphastar Pharmaceuticals (AMPH), Alpha Metallurgical Resources (AMR) and Riley Exploration Permian (REPX) have been selected as the top picks with a high net income ratio.

Zacks Equity Research

Strength Seen in Amphastar (AMPH): Can Its 6.4% Jump Turn into More Strength?

by Zacks Equity Research

Amphastar (AMPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Select Medical (SEM) Buys Richmond Post-Acute Care Facility

by Zacks Equity Research

Select Medical (SEM) acquires the Vibra Hospital of Richmond to provide enhanced critical illness recovery care across Virginia.

Zacks Equity Research

Here's Why You Should Retain Molina (MOH) in Your Portfolio

by Zacks Equity Research

Molina's (MOH) inorganic growth activities, financial flexibility and cost-cutting initiatives poise it well for growth.

Zacks Equity Research

Here's What Makes UnitedHealth Group (UNH) a Lucrative Bet Now

by Zacks Equity Research

UnitedHealth Group (UNH) is well-poised for growth on the back of a growing customer base within its government businesses, efficient telehealth services and solid cash-generating abilities.

Zacks Equity Research

Centene (CNC) Expands Evolent Partnership to Boost Quality

by Zacks Equity Research

Centene (CNC) expands the use of Evolent's oncology specialty care to improve cost management.

Zacks Equity Research

HCA Healthcare (HCA) Expands in Kansas With a Medical Plaza

by Zacks Equity Research

HCA Midwest, run by HCA Healthcare (HCA), plans to add a two-story medical plaza in Overland Park of $12 million, to be occupied by Family Health Medical Group and Town Plaza Women's Care.

Zacks Equity Research

Is Addus HomeCare (ADUS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Addus HomeCare (ADUS) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Zacks Equity Research

Universal Health (UHS) Up 26% in 6 Months: More Room to Run?

by Zacks Equity Research

Universal Health (UHS) is well-poised for growth on the back of improved patient volumes, acquisitions and robust cash-generating abilities.

Zacks Equity Research

Here's Why You Should Retain Acadia (ACHC) in Your Portfolio

by Zacks Equity Research

Diversified revenue base, improving top line, strategic expansion initiatives and joint ventures poise Acadia Healthcare (ACHC) well for growth.

Zacks Equity Research

Select Medical (SEM) Forays Into Indiana With Lutheran Health JV

by Zacks Equity Research

Select Medical (SEM) partners with Lutheran Health Network to enhance critical illness recovery and inpatient rehabilitation services in Fort Wayne and neighborhood communities.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH)'s Technical Outlook is Bright After Key Golden Cross

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Ethan Feller headshot

2 Stocks to Buy Now After Powell Flips the Narrative... Again

by Ethan Feller

Expectations for the next FOMC meeting have seen odds of a 50bps rate hike go from extremely unlikely to highly likely

Zacks Equity Research

Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Macro Headwinds

by Sundeep Ganoria

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Amphastar (AMPH) delivered earnings and revenue surprises of 92.11% and 6.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Bausch (BHC) delivered earnings and revenue surprises of 10.87% and 3.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bausch (BHC) Stock Jumps 19.3%: Will It Continue to Soar?

by Zacks Equity Research

Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Zacks Industry Outlook Highlights Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies

by Zacks Equity Research

Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies have been highlighted in this Industry Outlook article.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Inflation Pressures

by Sundeep Ganoria

The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.